Bristol adds medicine to patent pool for AIDS drugs

Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries. The licensing deal will enable generic drug firms around the world to produce affordable versions of atazanavir, which Bristol sells under the brand name Reyataz, and to combine it with other medicines to make treatment easier. The agreement announced on Thursday by the United Nations-backed Medicines Patent Pool is the first covering an HIV drug designed for use after patients develop resistance to initial treatments.
Sexual Health News Headlines – Yahoo! News